Vancouver's MedBioGene Inc (MBI) has finalized its commercialization, licence and research reimbursement agreement with Precision Therapeutics Inc, Pittsburgh, giving Precision exclusive global rights to commercialize its technology. LungExpressDX is a proprietary gene expression-based test to improve the identification of patients with early-stage, non-small-cell lung cancer with a higher risk of mortality following the removal of tumors. The technology is being developed by a teams of researchers at Princess Margaret Hospital/ University Health Network and led by Drs Frances Shepherd and Ming-Sound Tao. MBI is focused on the development and commercialization of gemomic-based personalized laboratory tests….